Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system

References

• Broms G, et al. Complications from inflammatory bowel disease during pregnancy and delivery. Clinic Gastroenterol Hepatol. 2012;10(11):1246–1252.
   PubMed Web of Science ®Google Scholar
• Bush MC, Patel S, Lapinski RH, et al. Perinatal outcomes in inflammatory bowel disease. J Maternal-Fetal Med. 2004;15(4):237–241.
   Google Scholar
• Broms G, et al. Birth outcomes in women with inflammatory bowel disease: effects of disease activity and drug exposure. Inflamm Bowel Dis. 2014;20(6):1091–1098.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Suarez B, Sengupta S, Moss AC. Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis. World J Gastroenterol. 2017;23(45):8082–8089.
   PubMed Web of Science ®Google Scholar
• Van Der Woude CJ, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohn’s & Colitis. 2015;9(2):107–124.
   PubMed Web of Science ®Google Scholar
• Nguyen GC, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150(3):734–757.e1.
   Web of Science ®Google Scholar
• Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19(17):2591–2602.
   PubMed Web of Science ®Google Scholar
• De Lima A, Zelinkova Z, Van Der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65(8):1261–1268.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, McConnell RA, Chambers CD. Drug safety and risk of adverse outcomes for pregnant patients with inflammatory bowel disease. Gastroenterology. 2017;152(2):451–462.e452.
   PubMed Web of Science ®Google Scholar
• De Lima-Karagiannis A, Zelinkova-Detkova Z, Van Der Woude CJ. The effects of active ibd during pregnancy in the era of novel IBD therapies. Am J Gastroenterol. 2016;111(9):1305–1312.
   PubMed Web of Science ®Google Scholar
• Kammerlander H, et al. The effect of disease activity on birth outcomes in a Nationwide Cohort of women with moderate to severe inflammatory bowel disease. Inflamm Bowel Dis. 2017;23(6):1011–1018.
   PubMed Web of Science ®Google Scholar
• De Lima A, Zelinkova Z, Mulders AG, et al. Preconception care reduces relapse of inflammatory bowel disease during pregnancy. Clinic Gastroenterol Hepatol. 2016;14(9):1285–1292.e1.
   PubMed Web of Science ®Google Scholar
• Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci. 2014;1317:32–38.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clinic Gastroenterol Hepatol. 2013;11(3):286–292. quiz e224.
   PubMed Web of Science ®Google Scholar
• Bortlik M, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-alpha therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48(8):951–958.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33(9):1053–1058.
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clinic Gastroenterol Hepatol. 2013;11(3):318–321.
   PubMed Web of Science ®Google Scholar
• Julsgaard M, et al. Concentrations of Adalimumab and Infliximab in mothers and newborns, and effects on infection. Gastroenterology. 2016;151(1):110–119.
   PubMed Web of Science ®Google Scholar
• Labetoulle R, Roblin X, Paul S. Prolonged persistence of adalimumab transferred from mother to infant during pregnancy. Ann Intern Med. 2018;169:60. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Porter C, et al. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016;116:7–12.
   PubMed Web of Science ®Google Scholar
• Mariette X, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233.
   PubMed Web of Science ®Google Scholar
• Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of pregnancy. Nat Rev Immunol. 2017;17(8):469–482.
   PubMed Web of Science ®Google Scholar
• Lee SK, et al. An imbalance in interleukin-17-producing T and Foxp3(+) regulatory T cells in women with idiopathic recurrent pregnancy loss. Hum Reprod. 2011;26(11):2964–2971.
   PubMed Web of Science ®Google Scholar
• Haider S, Knofler M. Human tumour necrosis factor: physiological and pathological roles in placenta and endometrium. Placenta. 2009;30(2):111–123.
   PubMed Web of Science ®Google Scholar
• Narula N, Al-Dabbagh R, Dhillon A, et al. Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(10):1862–1869.
   PubMed Web of Science ®Google Scholar
• Broms G, et al. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clinic Gastroenterol Hepatol. 2016;14(2):234–241.e231–235.
   PubMed Web of Science ®Google Scholar
• Mekinian A, et al. Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: is There a Place for Immunomodulation? Am J Reprod Immunol. 2016;76(1):8–28.
   PubMed Web of Science ®Google Scholar
• Winger EE, Reed JL. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am J Reprod Immunol. 2008;60(1):8–16.
   PubMed Web of Science ®Google Scholar
• Pasparakis M, Alexopoulou L, Episkopou V, et al. Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J Exp Med. 1996;184(4):1397–1411.
   PubMed Web of Science ®Google Scholar
• Kattah MG, et al. Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants. Clin Transl Gastroenterol. 2018;9(4):143.
   PubMedGoogle Scholar
• Esteve-Sole A, et al. Immunological changes in blood of newborns exposed to anti-TNF-alpha during pregnancy. Front Immunol. 2017;8:1123.
   PubMed Web of Science ®Google Scholar
• Bessissow T, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012;36(4):312–323.
   PubMed Web of Science ®Google Scholar
• Guiddir T, et al. Anti-TNF-alpha therapy may cause neonatal neutropenia. Pediatrics. 2014;134(4):e1189–1193.
   PubMed Web of Science ®Google Scholar
• Cheent K, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s disease. J Crohn’s & Colitis. 2010;4(5):603–605.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, et al. The London position statement of the World Congress of gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106(2):214–223. quiz 224.
   PubMed Web of Science ®Google Scholar
• Lu Y, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol. 2014;10(6):355–363.
   PubMedGoogle Scholar
• Vasiliauskas EA, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clinic Gastroenterol Hepatol. 2006;4(10):1255–1258.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Kane SV, Church JA, Vasiliauskas EA, et al. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology. 2008;134(Issue 4, Supplement 1):A–69.
   Web of Science ®Google Scholar
• Steenholdt C, Al-Khalaf M, Ainsworth MA, et al. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohn’s & Colitis. 2012;6(3):358–361.
   PubMed Web of Science ®Google Scholar
• Sheibani S, et al. The effect of maternal peripartum anti-TNFalpha use on infant immune response. Dig Dis Sci. 2016;61(6):1622–1627.
   PubMed Web of Science ®Google Scholar
• Beaulieu DB, et al. Use of biologic therapy by pregnant women with inflammatory bowel disease Does not affect infant response to vaccines. Clinic Gastroenterol Hepatol. 2018;16(1):99–105.
   PubMed Web of Science ®Google Scholar
• De Lima A, Kanis SL, Escher JC, et al. Hepatitis B vaccination effective in children exposed to anti-TNF alpha in utero. J Crohn’s & Colitis. 2018. Epub ahead of print. DOI:10.1093/ecco-jcc/jjy053
   Google Scholar
• Bortlik M, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis. 2014;20(3):495–501.
   PubMed Web of Science ®Google Scholar
• Chaparro M, et al. Long-term safety of in Utero exposure to anti-tnfalpha drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol. 2018;113(3):396–403.
   PubMed Web of Science ®Google Scholar
• Pereira R, Lago P, Faria R, et al. Safety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on infections and malignancy. Drug Dev Res. 2015;76(8):419–427.
   PubMed Web of Science ®Google Scholar
• Deepak P, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108(1):99–105.
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106(12):2146–2153.
   PubMed Web of Science ®Google Scholar
• Bryant RV, Sandborn WJ, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? J Crohn’s & Colitis. 2015;9(4):356–366.
   PubMed Web of Science ®Google Scholar
• Rosario M, et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of Vedolizumab. Clin Pharmacokinet. 2017;56(11):1287–1301.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, et al. Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45(7):941–950.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, et al. 437 Do infant serum levels of biologic agents at birth correlate with risk of adverse outcomes? Results from the PIANO registry. Gastroenterology. 2016;150(4):S91–S92.
   Web of Science ®Google Scholar
• Darribere T, et al. Integrins: regulators of embryogenesis. Biol Cell. 2000;92(1):5–25.
   PubMed Web of Science ®Google Scholar
• Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development. 1995;121(2):549–560.
   PubMed Web of Science ®Google Scholar
• Bye WA, Jairath V, Travis SPL. Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2017;46(1):3–15.
   PubMed Web of Science ®Google Scholar
• Arroyo AG, Yang JT, Rayburn H, et al. Alpha4 integrins regulate the proliferation/differentiation balance of multilineage hematopoietic progenitors in vivo. Immunity. 1999;11(5):555–566.
   PubMed Web of Science ®Google Scholar
• Wyant T, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64(1):77–83.
   PubMed Web of Science ®Google Scholar
• Colombel JF, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851.
   PubMed Web of Science ®Google Scholar
• Singh N, et al. Multi-center experience of Vedolizumab effectiveness in pediatric inflammatory bowel disease. inflamm bowel dis. 2016;22(9):2121–2126.
   PubMed Web of Science ®Google Scholar
• Conrad MA, et al. Vedolizumab Therapy in severe pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2425–2431.
   PubMed Web of Science ®Google Scholar
• Deepak P, Sandborn WJ. Ustekinumab and Anti-Interleukin-23 Agents in Crohn’s Disease. Gastroenterol Clin North Am. 2017;46(3):603–626.
   PubMed Web of Science ®Google Scholar
• Van Mourik MS, Macklon NS, Heijnen CJ. Embryonic implantation: cytokines, adhesion molecules, and immune cells in establishing an implantation environment. J Leukoc Biol. 2009;85(1):4–19.
   PubMed Web of Science ®Google Scholar
• Ledee-Bataille N, et al. A new role for natural killer cells, interleukin (IL)-12, and IL-18 in repeated implantation failure after in vitro fertilization. Fertil Steril. 2004;81(1):59–65.
   PubMed Web of Science ®Google Scholar
• Sharma S, Godbole G, Modi D. Decidual control of trophoblast invasion. Am J Reprod Immunol. 2016;75(3):341–350.
   PubMed Web of Science ®Google Scholar
• Karmakar S, Dhar R, Das C. Inhibition of cytotrophoblastic (JEG-3) cell invasion by interleukin 12 involves an interferon gamma-mediated pathway. J Biol Chem. 2004;279(53):55297–55307.
   PubMed Web of Science ®Google Scholar
• Raghupathy R, Al-Azemi M, Azizieh F. Intrauterine growth restriction: cytokine profiles of trophoblast antigen-stimulated maternal lymphocytes. Clin Dev Immunol. 2012;(2012):734865.
   PubMedGoogle Scholar
• Cai J, Li M, Huang Q, et al. Differences in Cytokine expression and STAT3 activation between healthy controls and patients of Unexplained Recurrent Spontaneous Abortion (URSA) during early pregnancy. PloS One. 2016;11(9):e0163252.
   PubMed Web of Science ®Google Scholar
• Cai JY, Li MJ. Interleukin 23 regulates the functions of human decidual immune cells during early pregnancy. Biochem Biophys Res Commun. 2016;469(3):340–344.
   PubMed Web of Science ®Google Scholar
• Martin PL, et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol. 2010;89(5):351–363.
   PubMed Web of Science ®Google Scholar
• Venturin C, et al. Fetal death in utero and miscarriage in a patient with Crohn’s disease under therapy with ustekinumab: case-report and review of the literature. BMC Gastroenterol. 2017;17(1):80.
   PubMedGoogle Scholar
• Rowan CR, et al. Ustekinumab drug levels in maternal and cord blood in a woman with Crohn’s disease treated until 33 weeks of gestation. J Crohn’s & Colitis. 2018;12(3):376–378.
   PubMed Web of Science ®Google Scholar